Gland Pharma Limited (NSE: GLAND) reported Revenue from Operations of ₹938.28 Crore down from ₹1,063.32 Crore year on year, a decline of 11.8%. Consolidated Net Profit of ₹231.94 Crore, slumped 15% from ₹273 Crore in the same quarter of the previous year. The Earnings per Share is ₹14.08 for this quarter.
Gland Pharma Limited Q3 FY23; Net Profit Down To 232 Crore
Related Post
- Titan Company Ltd Q2FY25; 1.5% fall in Net Profits
Company Overview: Titan Company Ltd is among India’s most respected lifestyle companies. It has established…
-
Coal India Ltd Q2FY25; 22% fall in Profits
Coal India Ltd is mainly engaged in mining and production of Coal and also operates…
-
Cholamandalam Investment & Finance Company Ltd Q2FY25; 25% rise in Profits
Cholamandalam Investment & Finance Company is one of the premier diversified non-banking finance companies in…